DelveInsight’s “Uveitis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Uveitis, historical and forecasted epidemiology as well as the Uveitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Uveitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Uveitis Market Forecast
Some of the key facts of the Uveitis Market Report:
-
The Uveitis market size was valued approximately USD 1,544 Million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
-
In 2023, the United States held the largest market share for uveitis, with a value of approximately USD 813.44 million, surpassing the combined market sizes of the EU4 countries (Germany, Italy, France, and Spain), the UK, and Japan.
-
Within the EU4 and the UK, Germany boasted the highest market size, reaching around USD 118.28 million in 2023. Projections suggest this figure will rise further, with Germany anticipated to lead the market followed by the UK and France by 2034.
-
According to DelveInsight analysis, approximately 1 million diagnosed prevalent cases of uveitis were identified in the 7MM in 2023. This figure is anticipated to rise over the study period from 2020 to 2034.
-
Based on DelveInsight's analysis, the United States contributed the largest share, approximately 38%, of the total diagnosed prevalent cases of uveitis in the 7MM in 2023. It is projected that these cases will continue to rise by 2034.
-
In the United States, it was estimated that in 2023 there were around 34,351 cases of infectious uveitis and noninfectious uveitis, respectively. These figures are anticipated to undergo changes during the forecast period from 2024 to 2034.
-
In 2023, Japan reported roughly 214,000 diagnosed prevalent cases of uveitis. According to DelveInsight's analysis, these diagnosed prevalent cases are projected to decline by 2034.
-
Key Uveitis Companies: Tarsier Pharma, Oculis Pharma, Roche/Eleven Biotherapeutics, Eli Lilly and Company, Eyevensys, Acelyrin/Affibody Medical, Priovant Therapeutics (Roivant Sciences and Pfizer), Clearside Biomedical, Inc., Eli Lilly and Company, ACELYRIN Inc., AbbVie, National Eye Institute, AbbVie, Massachusetts Eye Research, Priovant Therapeutics, Inc., Alumis Inc, Quan Dong Nguyen, Soligenix, Ganzhou Hemay Pharmaceutical, Amgen, and others
-
Key Uveitis Therapies: TRS01, Licaminlimab (OCS-02), Vamikibart (RO720220/RG6179), OLUMIANT (baricitinib), EYS606, Izokibep, Brepocitinib, QLETLI, Bio-Thera Solutios, triamcinolone acetonide (Triesence®), Baricitinib, Izokibep, Adalimumab, B27PD, adalimumab, Ixekizumab Prefilled Syringe, Brepocitinib, ESK-001, OCS-01, Dusquetide, Hemay005, Apremilast, and others
-
The Uveitis epidemiology based on gender analyzed that noninfectious uveitis cases are higher in number than infectious uveitis cases
-
The Uveitis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Uveitis pipeline products will significantly revolutionize the Uveitis market dynamics.
Uveitis Overview
Uveitis is a condition characterized by inflammation of the uvea, which is the middle layer of the eye. The uvea consists of the iris, ciliary body, and choroid, and inflammation can affect one or more of these structures. Uveitis can be acute or chronic and may involve one or both eyes.
Get a Free sample for the Uveitis Market Report:
https://www.delveinsight.com/report-store/uveitis-market
Uveitis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Uveitis Epidemiology Segmentation:
The Uveitis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
-
Total Prevalence of Uveitis
-
Prevalent Cases of Uveitis by severity
-
Gender-specific Prevalence of Uveitis
-
Diagnosed Cases of Episodic and Chronic Uveitis
Download the report to understand which factors are driving Uveitis epidemiology trends @ Uveitis Epidemiology Forecast
Uveitis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Uveitis market or expected to get launched during the study period. The analysis covers Uveitis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Uveitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Uveitis Therapies and Key Companies
-
TRS01: Tarsier Pharma
-
Licaminlimab (OCS-02): Oculis Pharma
-
Vamikibart (RO720220/RG6179): Roche/Eleven Biotherapeutics
-
OLUMIANT (baricitinib): Eli Lilly and Company
-
EYS606: Eyevensys
-
Izokibep: Acelyrin/Affibody Medical
-
Brepocitinib: Priovant Therapeutics (Roivant Sciences and Pfizer)
-
QLETLI: Bio-Thera Solutions
-
triamcinolone acetonide (Triesence®): Clearside Biomedical, Inc.
-
Baricitinib: Eli Lilly and Company
-
Izokibep: ACELYRIN Inc.
-
Adalimumab: AbbVie
-
B27PD: National Eye Institute
-
adalimumab: AbbVie
-
Ixekizumab Prefilled Syringe: Massachusetts Eye Research
-
Brepocitinib: Priovant Therapeutics, Inc.
-
ESK-001: Alumis Inc
-
OCS-01: Quan Dong Nguyen
-
Dusquetide: Soligenix
-
Hemay005: Ganzhou Hemay Pharmaceutical
-
Apremilast: Amgen
Discover more about therapies set to grab major Uveitis market share @ Uveitis Treatment Market
Uveitis Market Strengths
-
The remarkable advances in ocular immunology over the past decades have led to a better understanding of the molecular mechanisms that underlie etiology and susceptibility to uveitis
-
New drugs with diverse mechanisms of action and routes of administration have been approved in the recent past, improving the treatment regime
Uveitis Market Opportunities
-
Opportunity for companies to implement knowledge from recent advances in understanding the etiologies associated with uveitis to evaluate potential drugs with novel targets
-
Biomarker discovery and proteomics provide potential targets for therapeutic intervention by the drugs that are available and accessible, besides providing information about the drug that can be avoided
Scope of the Uveitis Market Report
-
Study Period: 2020–2034
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Uveitis Companies: Tarsier Pharma, Oculis Pharma, Roche/Eleven Biotherapeutics, Eli Lilly and Company, Eyevensys, Acelyrin/Affibody Medical, Priovant Therapeutics (Roivant Sciences and Pfizer), Clearside Biomedical, Inc., Eli Lilly and Company, ACELYRIN Inc., AbbVie, National Eye Institute, AbbVie, Massachusetts Eye Research, Priovant Therapeutics, Inc., Alumis Inc, Quan Dong Nguyen, Soligenix, Ganzhou Hemay Pharmaceutical, Amgen, and others
-
Key Uveitis Therapies: TRS01, Licaminlimab (OCS-02), Vamikibart (RO720220/RG6179), OLUMIANT (baricitinib), EYS606, Izokibep, Brepocitinib, QLETLI, Bio-Thera Solutios, triamcinolone acetonide (Triesence®), Baricitinib, Izokibep, Adalimumab, B27PD, adalimumab, Ixekizumab Prefilled Syringe, Brepocitinib, ESK-001, OCS-01, Dusquetide, Hemay005, Apremilast, and others
-
Uveitis Therapeutic Assessment: Uveitis current marketed and Uveitis emerging therapies
-
Uveitis Market Dynamics: Uveitis market drivers and Uveitis market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
Uveitis Unmet Needs, KOL’s views, Analyst’s views, Uveitis Market Access and Reimbursement
To know more about Uveitis companies working in the treatment market, visit @ Uveitis Clinical Trials and Therapeutic Assessment
Table of Contents
1. Uveitis Market Report Introduction
2. Executive Summary for Uveitis
3. SWOT analysis of Uveitis
4. Uveitis Patient Share (%) Overview at a Glance
5. Uveitis Market Overview at a Glance
6. Uveitis Disease Background and Overview
7. Uveitis Epidemiology and Patient Population
8. Country-Specific Patient Population of Uveitis
9. Uveitis Current Treatment and Medical Practices
10. Uveitis Unmet Needs
11. Uveitis Emerging Therapies
12. Uveitis Market Outlook
13. Country-Wise Uveitis Market Analysis (2020–2034)
14. Uveitis Market Access and Reimbursement of Therapies
15. Uveitis Market Drivers
16. Uveitis Market Barriers
17. Uveitis Appendix
18. Uveitis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
